image credit: Freepik

Merck ups the stakes in pneumococcal jab face-off with Pfizer

June 22, 2022


One of these – dubbed V116 – is a cocktail of 21 Streptococcus pneumoniae serotypes designed to have the most benefit in adult populations, and it has just cleared a phase 1/2 trial as it embarks on a phase 3 programme.

It’s a companion shot to Merck’s Vaxneuvance (formerly V114), which covers 15 serotypes and was approved by the FDA last year as a rival to Pfizer’s Prevnar 13 and newer Prevnar 20 vaccines, which cover 13 and 20 serotypes, respectively.

Read More on Pharmaphorum